Our global team has deep scientific knowledge, extensive pharmaceutical experience as well as proven clinical and business acumen.
Laura Benjamin, PhD
Founder and CEO
PhD in Molecular Biology from the University of Pennsylvania
BA in Biology from Barnard College, Columbia University
Laura brings scientific vision and leadership experience from her years as faculty at Harvard Medical School and Vice President at ImClone Systems and Eli Lilly. She has focused her scientific career on cancer biology and clinical biomarker strategies.
David Malek, MBA
Chief Business Officer
MBA from Tuck School of Business, Dartmouth College
David brings experience in business development as well as executive managerial experience in public companies, Sanofi and BiolineRx.
Jessicca Rege, PhD
Chief Development Officer
PhD in Pharmaceutical Sciences Virginia Commonwealth University
MS in Physiology from Virginia Commonwealth University
BA in Biology from Carson Newman College
Jessicca is an experienced oncology leader with over ten years of experience in the pharmaceutical field. She most recently served as Global Chief of Staff for the Cancer Enterprise in Daiichi-Sankyo where she took a central role in supporting the Global Head of Oncology R&D in both strategic planning and implementation of their global portfolio. Prior to this, she held various leadership roles in both large and small pharmaceutical companies in both clinical development and medical affairs supporting the development and approval of oncology products, such as Cyramza® , Halaven®, Lenvima®, and Sprycel®.
Hagop Youssoufian, MD
Acting Chief Medical Officer
MD from University of Massachusetts Medical School
Fellowships in Genetics at Johns Hopkins and
Hematology-Oncology at Massachusetts General Hospital
Hagop is an experienced oncology drug developer with tenures in several pharmaceutical and biotech companies, including as Chief Medical Officer at ImClone-Lilly and as President of R&D at Ziopharm. He was involved in the development and approval of multiple oncology biologic products, such as Erbitux®, Cyramza®, and Taxotere®.